Pharmidex to support the MRC in 2010
Pharmidex will provide all in vivo ADME/PK drug discovery support to the MRCt in 2010. MRCt have chosen Pharmidex as their partner of choice since they continue to provide high quality, fast-turnaround ADME/PK data cost effectively. Gary Manchee, global Head of Business Development at Pharmidex concludes that the attraction of Pharmidex as the partner of choice lies in the range of services offered, the high quality of the data, the ability to design studies to fast-forward discovery programmes and the “no-cost“ intellectual input available to ensure maximum benefit to our client.